Syros Pharmaceuticals Inc (NASDAQ:SYRS) has a beta value of 1.65 and has seen 8.48 million shares traded in the last trading session. The company, currently valued at $2.46M, closed the last trade at $0.09 per share which meant it gained $0.01 on the day or 11.84% during that session. The SYRS stock price is -7977.78% off its 52-week high price of $7.27 and 22.22% above the 52-week low of $0.07.
The consensus among analysts is that Syros Pharmaceuticals Inc (SYRS) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Sporting 11.84% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SYRS stock price touched $0.09 or saw a rise of 5.16%. Year-to-date, Syros Pharmaceuticals Inc shares have moved -60.14%, while the 5-day performance has seen it change 11.71%. Over the past 30 days, the shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) have changed -49.20%.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 98.2% from current levels. The projected low price target is $5.0 while the price target rests at a high of $5.0. In that case, then, we find that the current price level is -5455.56% off the targeted high while a plunge would see the stock gain -5455.56% from current levels.
Syros Pharmaceuticals Inc (SYRS) estimates and forecasts
The company’s shares have lost -94.01% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -100.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 21.16% over the past 5 years. Earnings growth for 2025 is a modest 74.11% while over the next 5 years, the company’s earnings are expected to increase by 52.99%.
SYRS Dividends
Syros Pharmaceuticals Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 0.96% shares in the company for having 257.63 shares of worth $23599.0 while later fund manager owns 98.67 shares of worth $9038.0 as of Dec 31, 2024 , which makes it owner of about 0.37% of company’s outstanding stock.
